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ORIGINAL ARTICLE
Tourette syndrome (TS) is a chronic neuropsy-
chiatric disorder that is characterized by motor
and vocal tics. Diagnosis is based solely on clini-
cal criteria. The prevalence of this syndrome is
estimated to be between one and 10 per 1000
children and adolescents.1 A variety of neurotrans-
mitters have been implicated in the pathophy-
siology of TS, and a variety of pharmacological
agents have been used for the treatment of patients
with tics, including agonists and/or antagonists
for dopamine, serotonin, norepinephrine, acetyl-
choline, γ-aminobutyric acid and opioid systems.1,2
Traditional antipsychotics are still the mainstay of
pharmacological treatment for TS, and haloperi-
dol remains the most frequently prescribed med-
ication for the disorder.3 However, many patients
experience intolerable adverse effects, including se-
dation, extrapyramidal symptoms, akathisia, and
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Background/Purpose: Tourette syndrome (TS) is characterized by motor and vocal tics, and its diagnosis
is based on clinical criteria. Dopamine-blocking neuroleptics are regarded as the most effective drugs for
the treatment of TS. Sulpiride is a selective dopamine D2 antagonist. However, only one study with a large
number of patients has reported the effect of treatment of TS with sulpiride. The purpose of this study was
to evaluate prospectively the effect of sulpiride treatment of children and adolescents with TS or chronic
tic disorder.
Methods: The inclusion criteria were patients who fulfilled the diagnosis of TS or chronic tic disorder, and
who had not received previous treatment. The severity of TS was assessed by the Yale Global Tic Severity
Score (YGTSS) every 2 weeks for a total of 6 weeks. The patients started treatment with low-dose sulpiride
according to their age on the first visit. The adverse effects of sulpiride were evaluated by subjective com-
plaints from the patients themselves or their parents. The change in scores between each assessment point
was analyzed by repeated measures one-way analysis of variance, with SPSS version 12.0 software.
Results: One hundred and eighty-nine patients were enrolled. Their average age was 8.0 ± 2.5 years (range,
3–15 years). Most patients were male (n = 165, 87.3%). Six weeks’ treatment significantly improved motor
tics (p < 0.05), vocal tics (p < 0.05) and total YGTSS (p < 0.05). The most commonly encountered adverse
effect was sedation (n = 31, 16.4%).
Conclusion: Sulpiride is effective for short-term treatment of children and adolescents with TS or chronic
tic disorder, and has few adverse effects. [J Formos Med Assoc 2009;108(10):788–793]
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weight gain, which lead to two-thirds of patients
who show improvement with treatment choosing
to discontinue haloperidol.4
Of the other several potential therapeutic 
antipsychotics, dopamine-blocking neuroleptics
seem to be the most effective drugs for the treat-
ment of TS, although the role of dopamine in tics
is still controversial. Sulpiride is a selective dop-
amine D2 antagonist with antipsychotic and an-
tidepressant activity, and is also cost-effective. In
a retrospective study in 1990, Robertson et al re-
ported a 59% reduction in severity of TS in 63
patients treated with sulpiride.5 The mean age of
the patients was 29.3 years (range, 10–68 years)
and only 10 of them were treated with sulpiride
as a first-line agent. In the sulpiride responders,
who included adults and children, the most com-
monly prescribed daily dose was 400 mg. To date,
this is believed to be the only study with a rela-
tively large number of patients.
We conducted an open-label study to assess
prospectively the potential effect of a lower dose
of sulpiride in children and adolescents with TS
or chronic tic disorder.
Patients and Methods
We recruited children and adolescents with TS or
chronic tic disorder who agreed to participate in
the study, and were not taking any tic-suppressing
medication. Informed consent was obtained from
all the parents. TS or chronic tic disorder was diag-
nosed by two experienced pediatric neurologists
(CS Ho and NC Chiu) at our outpatient clinic be-
tween January 2005 and December 2007, on the
basis of the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, Text Revision (DSM-
IV-TR; American Psychiatric Association, 2000).
The severity of TS was assessed by the Yale Global
Tic Severity Score (YGTSS).6 This scale consists of
ratings for motor and vocal tics, in terms of num-
ber, frequency, intensity, complexity, and inter-
ference. The YGTSS has excellent interactive
reliability.6 We rated the scores at the first clinic
visit as the baseline scores and then every 2 weeks,
for a total of 6 weeks of follow-up. The clinical
rating at each visit was recorded by the same clini-
cians to avoid personal bias in severity evaluation.
All the patients started with low-dose sulpiride
according to their age at the first visit. For pa-
tients aged > 7 years, the initial dose was 100 mg
twice daily (half a 200-mg tablet). For patients
aged ≤ 7 years, the initial dose was 67 mg twice
daily (a third of a 200-mg tablet). The dose was
increased every 2 weeks (50–100 mg/day) if the
YGTSS did not show improvement and no in-
tolerable adverse effects were experienced. The 
adverse effects of sulpiride were evaluated by
subjective complaint from the patients themselves
or their parents, by questionnaire. At the end of
the study, the average sulpiride dose in patients
≤ 7 years of age was 156 mg/day, and in patients
> 7 years of age, it was 205 mg/day.
The baseline scores, including motor tic, vocal
tic and total scores, were compared with the scores
at weeks 2, 4 and 6. The serial score changes 
were analyzed by one-way analysis of variance
(ANOVA), with group as a between-subject fac-
tor, to compare symptom severity at the various
assessment points, measured with SPSS version
12.0 software (SPSS Inc., Chicago, IL, USA).
Results
Of the 198 patients recruited, 189 (171 children
and 18 adolescents) completed the trial. Five pa-
tients were lost to follow-up and four were with-
drawn from the study because they received
more than one antipsychotic agent in addition 
to sulpiride. The mean age was 8.0 ± 2.5 years
(range, 3–15 years). There were 165 male and 24
female patients. One hundred and thirteen pa-
tients fulfilled the criteria of TS, and another 71
had chronic motor tic disorder and five had
chronic vocal tic disorder. At baseline, the average
motor tic score evaluated by YGTSS was 12.71 ±
0.24; the average vocal tic score was 6.59 ± 0.46;
and the mean total YGTSS was 32.72 ± 0.89. At
the end of the study (week 6), the average motor
tic score was 6.45 ± 0.59; the average vocal tic score
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Table 1. Comparison of motor tic scores between baseline and weeks 2, 4 and 6
Score (A) (mean ± SD) Score (B) Mean difference (A − B) 95% CI p
Baseline (12.71 ± 0.24) Week 2 2.22 0.87 to 3.58 0.000*
Week 4 2.71 1.15 to 4.28 0.000*
Week 6 6.26 4.68 to 7.84 0.000*
Week 2 (10.49 ± 0.39) Baseline −2.22 −3.58 to −0.87 0.000*
Week 4 0.49 −1.24 to 2.22 0.890
Week 6 4.04 2.29 to 5.79 0.000*
Week 4 (10.00 ± 0.56) Baseline −2.71 −4.28 to −1.15 0.000*
Week 2 −0.49 −2.22 to 1.24 0.890
Week 6 3.55 1.63 to 5.46 0.000*
Week 6 (6.45 ± 0.59) Baseline −6.26 −7.84 to −4.68 0.000*
Week 2 −4.04 −5.79 to −2.29 0.000*
Week 4 −3.55 −5.46 to −1.63 0.000*
*p < 0.05, one-way analysis of variance. SD = standard deviation; CI = confidence interval.
Table 2. Comparison of vocal tic scores between baseline and weeks 2, 4 and 6
Score (A) (mean ± SD) Score (B) Mean difference (A − B) 95% CI p
Baseline (6.59 ± 0.46) Week 2 0.75 −1.21 to 2.71 0.762
Week 4 1.47 −0.79 to 3.74 0.345
Week 6 4.22 1.93 to 6.51 0.000*
Week 2 (5.84 ± 0.56) Baseline −0.75 −2.71 to 1.21 0.762
Week 4 0.72 −1.79 to 3.23 0.886
Week 6 3.47 0.93 to 6.00 0.002*
Week 4 (5.12 ± 0.65) Baseline −1.47 −3.74 to 0.79 0.345
Week 2 −0.72 −3.23 to 1.79 0.886
Week 6 2.75 −3.18 to 5.52 0.054
Week 6 (2.38 ± 0.47) Baseline −4.22 −6.51 to −1.93 0.000*
Week 2 −3.47 −6.00 to −0.93 0.002*
Week 4 −2.75 −5.52 to 3.18 0.054
*p < 0.05, one-way analysis of variance. SD = standard deviation; CI = confidence interval.
was 2.38 ± 0.47; and the average total YGTSS was
13.36 ± 1.43. This represented a mean reduction
of 49% in motor tic score, 64% in vocal tic score,
and 59% in total YGTSS. Vocal tics were more re-
sponsive to sulpiride than were motor tics. All
except three patients had a reduced severity score
at week 6 compared with baseline. Two of the ex-
ceptions underwent examination at school and
one had a common cold during therapy. In the
one-way ANOVA, a significant drug effect was
found between each assessment point, except 
between weeks 2 and 4 (Tables 1–3). There was a
significant reduction in motor tic scores (Table 1)
and total YGTSS (Table 3) between baseline and
weeks 2, 4 and 6; however, vocal scores were only
significantly reduced between baseline and week
6 (Table 2). There was no significant reduction in
scores between weeks 2 and 4 in motor tics, vocal
tics and total YGTSS. Mean age, baseline mean
score, and week 6 mean score for TS, chronic
motor tic and chronic vocal tic patients are out-
lined in Table 4. Compared with baseline YGTSS,
significant improvement after 6 weeks of treat-
ment was seen for motor tics (p < 0.05), vocal tics
(p < 0.05) and total YGTSS (p < 0.05; Figure).
The mean initial treatment dose was 176 mg/
day and the mean treatment dose at the end of the
study was 190 mg/day, which was not a significant
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change. The most common adverse effect with
sulpiride treatment was sedation early in the trial
(n = 31, 16.4%). However, in none of the patients
was sedation severe enough to interfere with
daily activity or school performance. The second
most common adverse effect was increased ap-
petite (n = 14, 7.4%). One patient reported a body
weight gain of 2 kg after 6 weeks of treatment. The
adverse effects are listed in Table 5. None of our
patients experienced extrapyramidal symptoms.
Discussion
TS is characterized by multiple motor tics plus
one or more vocal (phonic) tics, which charac-
teristically wax and wane. TS is now recognized
to be associated with a wide variety of associated
behaviors and psychopathology.7 The most com-
monly prescribed medications for motor and vocal
tics have been the dopamine antagonists. The most
successful agents in this group are haloperidol,
pimozide, sulpiride and tiapride, whereas risperi-
done and ziprasidone are two atypical neuro-
leptics with proven tic-suppressing efficacy.5,8–13
Haloperidol, a butyrophenone derivative, is pri-
marily a dopamine D2 receptor blocker.14 It is
one of the most widely prescribed agents used in
treating TS in the United States, Canada, United
Kingdom, Europe, Australasia and the Far East.7
However, it has been suggested that haloperidol
produces unacceptable adverse effects in 84% of
patients, and therefore, only a minority of 20–30%
of TS patients continue treatment for extended
periods.15
Atypical neuroleptics are believed to have a
low risk of tardive dyskinesia and acute extra-
pyramidal reactions. As a result of potential QT
changes, baseline and follow-up electrocardiog-
raphy is recommended for risperidone, ziprasi-
done and pimozide. It is also essential for the
prescribing clinician to be familiar with potential
Table 3. Comparison of total YGTSS scores between baseline and weeks 2, 4 and 6
Score (A) (mean ± SD) Score (B) Mean difference (A − B) 95% CI p
Baseline (32.72 ± 0.89) Week 2 5.15 0.93 to 9.38 0.009*
Week 4 8.19 3.31 to 13.08 0.000*
Week 6 19.37 14.43 to 24.30 0.000*
Week 2 (27.57 ± 1.16) Baseline −5.15 −9.38 to −0.93 0.009*
Week 4 3.04 −2.37 to 8.45 0.479
Week 6 14.21 8.75 to 19.67 0.000*
Week 4 (24.53 ± 1.64) Baseline −8.19 −13.08 to −3.31 0.000*
Week 2 −3.04 –8.45 to 2.37 0.479
Week 6 11.17 5.18 to 17.16 0.000*
Weez 6 (13.36 ± 1.43) Baseline −19.37 −24.30 to −14.43 0.000*
Week 2 −14.21 −19.67 to −8.75 0.000*
Week 4 −11.17 −17.16 to −5.18 0.000*
*p < 0.05, one-way analysis of variance. YGTSS = Yale Global Tic Severity Score; SD = standard deviation; CI = confidence interval.
Table 4. Mean age, baseline mean score and week 6 mean score of three groups of patients
Tourette’s syndrome Chronic motor tic disorder Chronic vocal tic disorder 
(n = 113) (n = 71) (n = 5)
Mean age (yr) 8.18 ± 0.25 7.91 ± 0.29 6 ± 0.71
Baseline mean score 37.26 ± 1.08 26.41 ± 1.25 23.75 ± 3.09
Week 6 mean score 14.49 ± 1.65 11.26 ± 3.15 17 ± 0.21
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cytochrome-P450-related drug reactions, because
fatal interactions have arisen with pimozide and
erythromycin-related antibiotics.16
The substituted benzamides, selective D2 an-
tagonists, have become popular for the treatment
of motor and vocal tics, and produce less extra-
pyramidal side effects and tardive dyskinesia.7
The most widely documented benzamide for treat-
ment of TS is sulpiride, first used by Yvonneau
and Bezard in 1970.17 In the only double-blind
trial with this drug, George et al undertook a 14-
week placebo-controlled, crossover study of fluvox-
amine versus sulpiride, followed by single-blind
combined treatment in 11 patients with comorbid
TS and obsessive–compulsive disorder (OCD).
Sulpiride monotherapy greatly reduced tics and
non-significantly improved OCD symptoms.10
Robertson et al managed 63 of 114 (55%) TS pa-
tients (mean age, 29.3 years) with sulpiride, and
found that beneficial effects occurred in 59% of
patients. Positive effects were: decreased motor
and vocal tics; OCD; aggression; echophenomena
and tension; and improved mood. The dose of
sulpiride in their study commenced at 200 mg/
day and increased to a limit of 1 g/day.5
In our study, most patients were male, with a
male to female ratio of 7:1, which is much higher
Table 5. Adverse effects of sulpiride treatment in
189 patients
Adverse effect Patients, n (%)
None 152 (80.4)
Sedation 31 (16.4)
Increased appetite 14 (7.4)
Headache 4 (2.1)
Depression 2 (1.1)
Abdominal pain 2 (1.1)
Dizziness 1 (0.5)
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Figure. YGTSS scores at each time point for: (A) motor
tics; (B) vocal tics; (C) total YGTSS scores. YGTSS = Yale
Global Tic Severity Score.
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than in previous studies, and implies that there
is a male predominance in TS of unknown cause.
With short-term sulpiride treatment in children
with TS or chronic tic disorder, we found signi-
ficant symptom reduction, which supports the
findings in previous studies. As far as we are aware,
our study was the second largest trial to date of
sulpiride treatment in patients with TS, and was
the largest study to show a good response to
sulpiride in children and adolescents with TS or
chronic tic disorder.
The most common adverse effect of sulpiride
is mild sedation, which is tolerable for all pa-
tients and often disappears at 1 or 2 weeks after
treatment. No extrapyramidal symptoms were
found with the low dose of sulpiride used in this
study. There was no tardive dyskinesia in the
study of Robertson et al,5 which further supports
our conclusion that sulpiride is a more accept-
able choice than haloperidol. The limitation of
our study is that most of our patients had disease
of mild to moderate severity according to the
YGTSS scale, and only a few patients had severe
symptoms at initial presentation. This probably
resulted from the younger patient age in our study
than in previous studies. We could not conclude
that sulpiride was effective in severe TS. However,
early intervention and treatment of tics are impor-
tant because long-standing symptoms may impair
a patient’s interpersonal relationships, academic
performance, or social activities.18 Further stud-
ies are necessary to assess the effect of sulpiride
treatment in patients with severe TS.
In conclusion, sulpiride is a good short-term
treatment choice for mild to moderate TS or
chronic tic disorder in children and adolescents.
Low-dose sulpiride is effective for treatment of TS
or chronic tic disorder and has few adverse effects.
References
1. Singer HS. Tourette’s syndrome: from behaviour to biology.
Lancet Neurol 2005;4:149–59.
2. Jankovic J. Tourette’s syndrome. N Engl J Med 2001;345:
1184–92.
3. Chappell PB, Scahill LD, Leckman JF. Future therapies 
of Tourette syndrome. Neurol Clin North Am 1997;15:
429–50.
4. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles
de la Tourette syndrome with clonidine and neuroleptics.
Arch Gen Psychiatry 1983;40:1235–40.
5. Robertson MM, Schnieden V, Lees AJ. Management 
of Gilles de la Tourette syndrome using sulpiride. Clin
Neuropharmacol 1990;13:229–35.
6. Leckman JF, Riddle MA, Hardin MT. The Yale Global Tic
Severity Scale: initial testing of a clinician-rated scale of tics
severity. J Am Acad Child Adolesc Psychiatry 1989;28:
566–73.
7. Robertson MM. Tourette syndrome, associated conditions
and the complexities of treatment. Brain 2000;123:425–62.
8. Eggers C, Rothenberger A, Berghaus U. Clinical and neu-
robiological findings in children suffering from tic disease
following treatment with tiapride. Eur Arch Psychiatry
Neurol Sci 1988;237:223–9.
9. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of
haloperidol and pimozide in children and adolescents with
Tourette’s disorder. Am J Psychiatry 1997;154:1057–62.
10. George MS, Trimble MR, Robertson MM. Fluvoxamine
and sulpiride in comorbid obsessive–compulsive disorder
and Gilles de la Tourette syndrome. Hum Psychopharmacol
1993;8:327–34.
11. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment
of children and adolescents with Tourette’s syndrome: 
a pilot study. J Am Acad Child Adolesc Psychiatry 2000;
39:292–9.
12. Bruggeman R, van der Linden C, Buitelaar JK, et al.
Risperidone versus pimozide in Tourette’s disorder: a com-
parative double-blind parallel-group study. J Clin Psychiatry
2001;62:50–6.
13. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled
trial of risperidone in Tourette syndrome. Neurology 2003;
60:1130–5.
14. Messiha FS. Biochemical pharmacology of Gilles de la
Tourette’s syndrome. Neurosci Biobehav Rev 1988;12:
295–305.
15. Chappell PB, Leckman JF, Riddle MA. The pharmacologic
treatment of tic disorders. Child Adolesc Psychiatr Clin N
Am 1995;4:197–216.
16. Leckman JF. Tourette’s syndrome. Lancet 2002;360:
1577–86.
17. Yvonneau M, Bezard P. Apropos of a case of Gilles de la
Tourette’s disease blocked by sulpiride. Psycho-biological
study. Encephale 1970;59:439–59.
18. Jankovic J. Tourette’s syndrome. N Engl J Med 2001;345:
1184–92.
